Paradigm Biocapital Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-878,323	Closed	-$41.5M	–	39
2025 Q2	$41.5M	Buy	878,323 +250,900	+40%	+$10.2M	1.77%	17
2025 Q1	$24.5M	Sell	627,423 -1,144,788	-65%	-$49.3M	1.12%	22
2024 Q4	$96M	Buy	1,772,211 +840,731	+90%	+$42.9M	3.34%	11
2024 Q3	$47M	Buy	+931,480	New	+$43.6M	1.59%	20
2023 Q3	–	Sell	-369,615	Closed	-$18.9M	–	34
2023 Q2	$18.9M	Buy	+369,615	New	+$9.95M	1.46%	28

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Paradigm Biocapital Advisors's MLTX Position: Q3 2025 in Review

Paradigm Biocapital Advisors sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 878,323 shares — an estimated $41.5M sold.

Paradigm Biocapital Advisors first reported a position in MLTX in Q2 2023 and held it in 5 quarters. The position peaked at $96M in Q4 2024. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

Paradigm Biocapital Advisors reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
Paradigm Biocapital Advisors sold 878,323 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $41.5M.
Paradigm Biocapital Advisors first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 5 quarters.
Paradigm Biocapital Advisors's MoonLake Immunotherapeutics position peaked at $96M in Q4 2024.
134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.